伊瓦布拉丁在临床实践中获得批准和其他用途:系统性审查
Mohsen Hajiqasemi1, Mandana Ebrahimzade1, Zahra A Ghelichkhan2
1Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Journal of cardiovascular pharmacology
|July 19, 2024
概括
伊瓦布拉丁 (IVA) 有效地降低了心率,为心力衰竭和冠状动脉疾病患者提供了比塔抑制剂的替代品. 它还显示出对POTS和不适当的鼻高心率等疾病的承诺.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心率 (HR) 是心血管疾病和心力衰竭 (HF) 的关键预后指标.
- β-阻断剂是标准的HR降低剂,但可能受到药物不耐受性的限制.
- 伊瓦布拉丁 (IVA) 是一种选择性的If电流抑制剂,作用于鼻腔节点心脏起器细胞.
研究的目的:
- 审查伊瓦布拉丁的临床应用,作用机制和结果.
- 探索伊瓦布拉丁在标签和非标签患者群体中的作用.
主要方法:
- 在PubMed进行了全面的文献搜索,截至2024年1月.
- 关键词包括伊瓦布拉丁,冠状动脉疾病 (CAD),心力衰竭 (HF),姿态性心律障碍综合征 (POTS) 和心律障碍.
- 包括141项研究,包括随机对照试验和观察性研究.
主要成果:
- 伊瓦布拉丁是一种可行的替代品,可用于治疗心力衰竭的β-阻塞剂,减少喷射分数和患有禁忌或不耐受症的CAD患者.
- 标签外使用表明在姿态心动节拍综合征和不适当的鼻腔心动节拍中减少HR的有效性.
- 伊瓦布拉丁还显示了冠状动脉计算机断层扫描血管学前期治疗的好处.
结论:
- 伊瓦布拉丁为HR控制提供了一种独特的机制,有可能用于更广泛的临床应用.
- 它在特定患者群体中的有效性需要进一步调查,并在治疗指南中加以考虑.
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
732
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
732
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
962
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
962
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
820
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
820
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
01:26Heart Failure Drugs: Inotropic Agents
563
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563